San Diego, California, United States In 2002 was created NantKwest, which is appeared as Corporate Investor. The main department of described Corporate Investor is located in the San Diego. The fund was located in North America if to be more exact in United States.
The typical case for the fund is to invest in rounds with 4 participants. Despite the NantKwest, startups are often financed by Lilly Ventures, Forward Ventures, DeNovo Ventures. The meaningful sponsors for the fund in investment in the same round are Wicklow Capital, Latterell Venture Partners, Forward Ventures. In the next rounds fund is usually obtained by Taiwania Capital, SalubrisBio.
The fund is generally included in less than 2 deals every year. The top activity for fund was in 2017. The usual things for fund are deals in the range of 10 - 50 millions dollars.
Among the most successful fund investment fields, there are Biotechnology, Biopharma. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Viracta Therapeutics
Related Funds
| Fund Name | Location |
| Harbert Growth Partners | Richmond, United States, Virginia |
| Motorola | Chicago, Illinois, United States |
| Penny Lane Advisors | - |
| RTI International | North Carolina, Raleigh, United States |
| Sidus Investment Management | New York, New York, United States |
| Suzhou Hengchuang Touzi | China, Jiangsu, Suzhou |
| Vital Venture Capital | Bethesda, Maryland, United States |
| Zee Entertainment Enterprises | India, Maharashtra, Mumbai |
| Zhuhai Gree Financial Investment Management | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Viracta Therapeutics | $18M | 04 Apr 2017 | California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Viracta Therapeutics | $18M | 04 Apr 2017 | California, United States |
